The development of an effective malaria vaccine has taken many decades, but there is now
a good chance that the first malaria vaccine will be licensed within the next few years …

Placental malaria, caused by sequestration of Plasmodium falciparum-infected erythrocytes
in the placenta, is associated with increased risk of maternal morbidity and poor birth …

Pregnancy‐associated malaria, a manifestation of severe malaria, is the cause of up to
200,000 infant deaths a year, through the effects of placental insufficiency leading to growth …

Background VAR2CSA is the lead antigen for developing a vaccine that would protect
pregnant women against placental malaria. A multi-system feasibility study has identified E …

Dear Editor, Pregnancy-associated malaria (PAM) threatened more than one million women
and their infants in endemic regions in 2019. This resulted in maternal anemia, stillbirth, and …

Cerebral malaria (CM) is the severest form of Plasmodium falciparum infection. Children
under 5 years old are those most vulnerable to CM, and they consequently have the highest …

Immune effector responses against Plasmodium falciparum include antibody-mediated
activation of innate immune cells, which can induce Fc effector functions, including antibody …

Despite recent efforts toward control and elimination, malaria remains a major public health
problem worldwide. Plasmodium falciparum resistance against artemisinin, used in front line …

Background: Plasmodium falciparum causes placental malaria, which results in adverse
outcomes for mother and child. P. falciparum-infected erythrocytes that express the parasite …

Background The pathogenesis of malaria in pregnancy (MiP) involves accumulation of P.
falciparum-infected red blood cells (pRBCs) in the placenta, contributing to poor pregnancy …